MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Abbott Laboratories

Slēgts

SektorsVeselības aprūpe

129.39 -0.45

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

128.02

Max

130.1

Galvenie mērījumi

By Trading Economics

Ienākumi

7.6B

9.2B

Pārdošana

339M

11B

P/E

Sektora vidējais

17.001

57.333

EPS

1.09

Dividenžu ienesīgums

1.8

Peļņas marža

84.099

Darbinieki

114,000

EBITDA

82M

3B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+11.42% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

1.80%

2.63%

Nākamais dividenžu datums

2025. g. 15. maijs

Nākamais Ex dividenžu datums

2025. g. 14. jūl.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

3B

225B

Iepriekšējā atvēršanas cena

129.84

Iepriekšējā slēgšanas cena

129.39

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Abbott Laboratories Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 16. apr. 16:21 UTC

Peļņas

Abbott Labs Bracing for Tariffs as Profits Rise -- Update

2025. g. 16. apr. 12:14 UTC

Peļņas

Abbott Labs 1Q Profit Jumps on Gains in Nutrition, Medical Devices

2025. g. 22. janv. 19:03 UTC

Peļņas

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

2025. g. 22. janv. 18:20 UTC

Peļņas

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

2025. g. 22. janv. 12:45 UTC

Peļņas

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

2025. g. 16. apr. 15:09 UTC

Tirgus saruna

Abbott Says Tariffs Killed Chances of an Outlook Raise -- Market Talk

2025. g. 16. apr. 14:17 UTC

Peļņas

Abbott Laboratories Stock Rises as First-Quarter Earnings Surpass Expectations -- Barrons.com

2025. g. 16. apr. 11:34 UTC

Peļņas

Abbott Labs 1Q Gross Margin of 52.8 % of Sales; Adj Gross Margin of 57.1 % >ABT

2025. g. 16. apr. 11:33 UTC

Peļņas

Abbott Labs Projects FY25 Adj Operating Margin to Be 23.5% to 24.0% of Sales >ABT

2025. g. 16. apr. 11:32 UTC

Peļņas

Abbott Labs Backs FY25 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025. g. 16. apr. 11:32 UTC

Peļņas

Abbott Labs Sees 2Q Adj EPS $1.23-Adj EPS $1.27 >ABT

2025. g. 16. apr. 11:31 UTC

Peļņas

Abbott Labs Projects FY25 Organic Sales Growth of 7.5% to 8.5% >ABT

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Reaffirms Full-Yr Guidance

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Labs 1Q Organic Sales Growth Up 6.9% >ABT

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Labs 1Q Sales $10.36B >ABT

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Labs 1Q Net $1.33B >ABT

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Labs 1Q EPS 76c >ABT

2025. g. 16. apr. 11:30 UTC

Peļņas

Abbott Labs 1Q Adj EPS $1.09 >ABT

2025. g. 16. apr. 09:57 UTC

Karstas akcijas

Stocks to Watch: Nvidia, AMD, Heineken, ASML -- WSJ

2025. g. 1. febr. 18:14 UTC

Top Ziņas

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

2025. g. 22. janv. 16:40 UTC

Top Ziņas
Peļņas

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

2025. g. 22. janv. 15:20 UTC

Peļņas

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

2025. g. 22. janv. 15:08 UTC

Peļņas

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025. g. 22. janv. 13:51 UTC

Peļņas

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

2025. g. 22. janv. 13:39 UTC

Top Ziņas
Peļņas

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

2025. g. 22. janv. 12:02 UTC

Peļņas

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

2025. g. 22. janv. 12:01 UTC

Peļņas

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

2025. g. 22. janv. 12:01 UTC

Peļņas

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

2025. g. 22. janv. 12:00 UTC

Peļņas

Abbott Labs 4Q Net $9.23B >ABT

Salīdzinājums

Cenas izmaiņa

Abbott Laboratories Prognoze

Cenas mērķis

By TipRanks

11.42% augšup

Prognoze 12 mēnešiem

Vidējais 144.15 USD  11.42%

Augstākais 159 USD

Zemākais 127 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Abbott Laboratories — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

18

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

128.52 / 129.7Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.